Enhancement in anti-tumor activity of Rituximab when combined with Epratuzumab or Apolizumab (Hu1D10) in a B-cell lymphoma severe combined immunodeficiency (SCID) mouse model.

被引：0
|
作者：
Hernandez-Ilizaliturri, F
Gada, P
Repasky, EA
Czuczman, MS
机构：
[1] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
591
引用
收藏
页码：158A / 158A
页数：1
相关论文
共 12 条
  • [1] Addition of immunomodulatory drugs CC5013 or CC4047 to rituximab enhances anti-tumor activity in a severe combined immunodeficiency (SCID) mouse lymphoma model.
    Hernandez-Ilizaliturri, FJ
    Reddy, N
    Holkova, B
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 70A - 70A
  • [2] The role of natural killer (NK) cell expansion and activation on the in vivo anti-tumor activity of immunomodulatory drug (IMiD) CC4047 plus rituximab in a severe combined immunodeficiency (SCID) lymphoma mouse model.
    Redd, NM
    Hernandez-Iizaliturri, FJ
    Czuczman, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 177S - 177S
  • [3] LIMITATIONS OF THE SEVERE COMBINED IMMUNODEFICIENCY (SCID) MOUSE MODEL FOR STUDY OF HUMAN B-CELL RESPONSES
    SOMASUNDARAM, R
    JACOB, L
    ADACHI, K
    CLASS, R
    SCHECK, S
    MARUYAMA, H
    HERLYN, D
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1995, 41 (04) : 384 - 390
  • [4] Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia.
    Hegde, U
    White, T
    Stetler-Stevenson, M
    Marti, G
    Janik, J
    Pittaluga, S
    Kingma, D
    Steinberg, S
    Cheson, B
    Jaffe, ES
    Wilson, WH
    BLOOD, 2002, 100 (11) : 358A - 358A
  • [5] Selinexor, a selective inhibitor of nuclear export (SINE) compound shows enhanced anti-tumor activity when combined with either venetoclax or bendamustine in diffuse large B cell lymphoma (DLBCL) mouse models
    Elloul, Sivan
    Chang, Hua
    Klebanov, Boris
    Kashyap, Trinayan
    Werman, Maxwell
    Lee, Margaret
    Landesman, Yosef
    Shacham, Sharon
    Kauffman, Michael
    Friedlander, Sharon Y.
    CANCER RESEARCH, 2016, 76
  • [6] Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma
    Mahadevan, Daruka
    Cooke, Laurence
    Liu, Xiaobing
    Persky, Daniel Oscar
    Spier, Catherine M.
    Miller, Thomas P.
    Qi, Wenqing
    BLOOD, 2010, 116 (21) : 1604 - 1604
  • [7] Concurrent administration of granulocyte colony-stimulating factor (G-CSF) or granulocyte-monocyte colony-stimulating factor (GM-CSF) enhance Rituximab's biological activity and upregulate CD11b in a severe combined immunodeficiency (SCID) mouse lymphoma model.
    Czuczman, MS
    Reising, S
    Repasky, EA
    Hernandez-Ilizaliturri, FJ
    BLOOD, 2002, 100 (11) : 157A - 157A
  • [8] Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity when combined with PD-1 blockade in a mouse model of colon cancer
    Elloul, Sivan
    Chang, Hua
    Klebanov, Boris
    Kashyap, Trinayan
    Werman, Maxwell
    Lee, Margaret
    Landesman, Yosef
    Shacham, Sharon
    Kauffman, Michael
    Friedlander, Sharon Y.
    CANCER RESEARCH, 2016, 76
  • [9] Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-Cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay
    Yoshida, M
    Rybak, RJ
    Choi, Y
    Greenberg, SJ
    Barcos, M
    Kawata, A
    Matsuno, F
    Tsai, H
    Seon, BK
    CANCER RESEARCH, 1997, 57 (04) : 678 - 685
  • [10] CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway
    Prins, R. C.
    Burke, R. T.
    Tyner, J. W.
    Druker, B. J.
    Loriaux, M. M.
    Spurgeon, S. E.
    LEUKEMIA, 2013, 27 (10) : 2094 - 2096
12